FORTIS
Fortis Healthcare Limited
Healthcare · Medical Care Facilities
Market price data is delayed by at least 15 minutes. Not for trading or investment decisions.
Fundamentals
Current Price
₹847.3
P/B Ratio
6.79
52W High
₹1,104.3
52W Low
₹635.2
Dividend Yield
12.00%
Profit Margin
10.94%
ROE
—
Debt / Equity
0.34
Sector
Healthcare
Industry
Medical Care Facilities
Peer Comparison same NSE industry · top 10 by 1M return
Hospital Healthcare Servicesas of 8 Apr 2026 close
| Symbol | Company | Price | P/B | RSI | 1M Ret | ROE | D/E |
|---|---|---|---|---|---|---|---|
| FORTISyou | Fortis Healthcare Limited | ₹840.55 | 6.74 | 57.5 | -4.3% | — | 0.33 |
| MEDIASSIST | Medi Assist Healthcare Servi | ₹362.05 | 4.39 | 65.6 | +20.8% | — | 0.52 |
| LAXMIDENTL | Laxmi Dental Limited | ₹192.12 | 4.50 | 62.6 | +10.5% | — | 0.04 |
| GAUDIUMIVF | Gaudium IVF and Women Health | ₹79.22 | 10.51 | 48.2 | +7.7% | — | — |
| RAINBOW | Rainbow Childrens Medicare L | ₹1,271.1 | 8.50 | 77.4 | +7.5% | — | 0.53 |
| SHALBY | Shalby Limited | ₹152.21 | 1.65 | 58.9 | +5.9% | — | 0.53 |
| YATHARTH | Yatharth Hospital & Trauma C | ₹702.45 | 4.01 | 61.7 | +5.7% | — | 0.02 |
| THYROCARE | Thyrocare Technologies Limit | ₹390.45 | 11.62 | 62.0 | +4.1% | — | 0.05 |
| FLAIR | Flair Writing Industries Lim | ₹307.85 | 3.01 | 55.7 | +2.9% | — | 0.05 |
| METROPOLIS | Metropolis Healthcare Limite | ₹456 | 6.59 | 48.3 | +2.3% | — | 0.14 |
| PARKHOSPS | Park Medi World Limited | ₹206.16 | 6.60 | 61.3 | +2.2% | — | 0.58 |
Price Chart
Quarterly Results Last 4 quarters
| Metric | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|
| Revenue | ₹2.3K Cr | ₹2.3K Cr | ₹2.2K Cr | ₹1.9K Cr |
| Gross Profit | ₹1.3K Cr | ₹1.3K Cr | ₹1.2K Cr | ₹992.8 Cr |
| Operating Income | ₹385.5 Cr | ₹450.5 Cr | ₹389.2 Cr | ₹323.6 Cr |
| Net Income | ₹193.7 Cr | ₹321.9 Cr | ₹260.3 Cr | ₹183.9 Cr |
Values in INR Crore. Source: yfinance / NSE filings.
SWOT Analysis AI · news + fundamentals
Strengths
- Fortis Healthcare has a strong market capitalization of approximately ₹609 billion, indicating robust investor confidence.
- The company has a relatively low debt-to-equity ratio of 0.3391, suggesting financial stability and lower financial risk.
Weaknesses
- The high P/E ratio of 63.52 indicates that the stock may be overvalued compared to its earnings, which could deter value investors.
- The return on equity (ROE) of 10.18% is relatively modest, suggesting that the company may not be maximizing shareholder returns effectively.
Opportunities
- Recent advancements in cancer treatment, as highlighted by the milestone in ALK lung cancer treatment, position Fortis to attract more patients and enhance its reputation.
- The growing demand for healthcare services in India presents opportunities for expansion and increased service offerings.
Threats
- Intense competition in the healthcare sector may pressure profit margins and market share.
- Regulatory changes in the healthcare industry could impact operational costs and profitability.
Recent News Sentiment
Fortis Hospital Bannerghatta Achieves Milestone in Advanced ALK Lung Cancer Treatment
+19Successful treatment of advanced lung cancer at Fortis Hospital highlights the hospital's capabilities in precision oncology.
Data sourced from yfinance and public NSE filings. Not investment advice.